ESH AL 2024 | The advantage of early blinatumomab treatment over chemotherapy in ALL
Mark Litzow, MD, Mayo Clinic Rochester, Rochester, MN, discusses the advantage of including blinatumomab in early lines of treatment for acute lymphoblastic leukemia (ALL), which showed a significant survival advantage over standard-of-care (SoC) chemotherapy regimens in the ECOG-E1910 trial (NCT02003222). However, the administration of this antibody by continuous intravenous infusion can be a challenge, which some studies have shown may be overcome by subcutaneous administration. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
